Short answer
Enliven Therapeutics, Inc. (ELVN) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$20M
- +13.0% YoY · +20.5% QoQ
- EPS (diluted)
- −$0.30
- +37.5% YoY · +37.5% QoQ
Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) Q3 2025 10-Q on SEC EDGAR. USD.
Enliven Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product or other revenue generated
- Net loss $20.1M vs $23.2M YoY; operating loss $25.1M vs $27.1M
- ELVN-001 R&D $4.7M vs $3.2M; ELVN-002 $2.3M vs $8.4M
- Cash, equivalents and marketable securities $477.6M at September 30, 2025
- Public Offering gross proceeds $230.0M; Sales Agreement proceeds $40.0M through September 30, 2025
Risk Factors
- ELVN-002 development exit by 2025, triggered by prioritization of ELVN-001’s upcoming pivotal trial
- ELVN-001 concentration risk, with revenue dependent heavily on successful clinical development and commercialization
- Regulatory approval risk, including potential FDA-required bridging studies for alternative tablet formulations
- Clinical execution risk, with ELVN-001 in Phase 1 and no completed clinical trials
- Funding risk, including $74.0 million nine-month net loss and $317.5 million accumulated deficit at September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Enliven Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.